Navigation Links
Going negative: Stanford scientists explore new technologies that remove atmospheric CO2
Date:2/16/2013

In his Feb. 12 State of the Union address, President Obama singled out climate change as a top priority for his second administration. "We can choose to believe that Superstorm Sandy, and the most severe drought in decades, and the worst wildfires some states have ever seen were all just a freak coincidence," he said. "Or we can choose to believe in the overwhelming judgment of science and act before it's too late."

Four years ago, the president addressed rising global temperatures by pledging a 17 percent cut in carbon dioxide (CO2) and other greenhouse gas emissions in the United States by 2020, and an 80 percent cut by 2050. The administration has taken a number of steps to meet those goals, such as investing billions of dollars in wind, solar and other carbon-neutral energy technologies.

But reducing CO2 emissions may not be enough to curb global warming, according to scientists at Stanford University. The solution, they say, could also require developing carbon-negative technologies that remove large amounts of CO2 from the atmosphere. Their findings are summarized in a report by Stanford's Global Climate and Energy Project (GCEP).

"To achieve the targeted cuts, we would need a scenario where, by the middle of the century, the global economy is transitioning from net positive to net negative CO2 emissions," said report co-author Chris Field, a professor of biology and of environmental Earth system science at Stanford. "We need to start thinking about how to implement a negative-emissions energy strategy on a global scale."

In the GCEP report, Field and lead author Jennifer Milne describe a suite of emerging carbon-negative solutions to global warming from bioenergy technologies to ocean sequestration. Many of the examples cited were initially presented at a negative carbon emissions workshop hosted by GCEP in 2012.

BECCS

"Net negative emissions can be achieved when more greenhouse gases are
'/>"/>

Contact: Mark Shwartz
mshwartz@stanford.edu
650-723-9296
Stanford University
Source:Eurekalert

Page: 1 2 3 4 5

Related biology news :

1. Going trayless study shows student impact
2. Protein production: Going viral
3. 23andMes Ancestry Composition reveals peoples ancestral origins going back 500+ years
4. Temple-Penn researchers identify calcium accelerator to keep cell power supply going
5. When the going gets tough, the tough get... more relief from a placebo?
6. Going with the flow
7. Preventing the immune system from going haywire during sepsis
8. The physics of going viral
9. Penn research points to new way of preserving fertility for boys undergoing cancer treatment
10. Stanford scientist uncovers the reproductive workings of a harvester ant dynasty
11. Stanford researcher sheds new light on the mysteries of spider silk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/30/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ... Gesture Recognition Market in Automotive Sector 2014-2018" report ... Global Gesture Recognition market in Automotive Sector to grow ... Gesture recognition is the ability of a ... an individual. Gesture recognition technology can be 2D-based or ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... new University of Central Florida study will examine how rising ... Florida Panhandle and Alabama and Mississippi coasts. The research, ... Engineering, is a response to scientific studies that show sea ... research also could potentially be linked with models of how ...
... German . An international team of researchers, including ... San Francisco (USA) and Dr. Shannon McPherron of the Max ... evidence that human ancestors were using stone tools and consuming ... earlier than previously documented. While working in the Afar region ...
... mantle reservoir on Baffin Island in the Canadian Arctic. Geologist ... the finding--the first discovery of what may be a primitive ... The Earth,s mantle is a rocky, solid shell that is ... up about 84 percent of the Earth,s volume. The mantle ...
Cached Biology News:Study to examine rising sea level's impact on estuaries, coastal communities 2Scientists discover oldest evidence of human stone tool use and meat-eating 2Scientists discover oldest evidence of human stone tool use and meat-eating 3Scientists discover oldest evidence of human stone tool use and meat-eating 4Oldest Earth mantle reservoir discovered 2
(Date:4/27/2015)... BRUNSWICK, New Jersey , 27 ... société de découverte médicamenteuse spécialisée dans ... antibiotiques destinés à soigner les infections ... aujourd,hui la présentation de données prouvant ... majeur, le TXA709, dans la lutte ...
(Date:4/27/2015)... , April 27, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today provided commentary on clinical study data ... a poster session at the American Association for ... ADXS31-164 is a novel Lm -LLO immunotherapy ...
(Date:4/27/2015)...  Haemonetics Corporation (NYSE: HAE ) today ... of $226.5 million, down 6%.  Excluding currency impact, ... Company reported a fourth quarter GAAP net loss ... net income, exclusive of transformation, restructuring and deal ... 1%, and adjusted earnings per share were $0.47, ...
(Date:4/27/2015)... Texas (PRWEB) April 27, 2015 ... for use in applications such as animal waste ... and oil reduction in wastewater treatment plants and ... an exhibitor at the Texas Commission on Environmental ... 5-6 in Austin, Texas. , The company will ...
Breaking Biology Technology:TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 2TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 3TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 4TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 5TAXIS Pharmaceuticals démontre la puissance clinique du TXA709 dans la lutte contre la résistance aux antibiotiques 6Aratana Therapeutics Comments on ADXS31-164 (AT-014) Study Data Presented During Poster Session at the American Association for Cancer Research (AACR) Annual Meeting 2015 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 2Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 3Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 4Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 5Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 6Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 7Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 8Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 9Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 10Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 11Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 12Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 13Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 14Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 15Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 16Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 17Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 18Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 19Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 20Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 21Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 22Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 23Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 24Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 25Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 26Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 27Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 28Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 29Haemonetics Reports 4th Quarter Fiscal 2015 Revenue of $226 Million and Adjusted EPS of $0.47; Full Year Revenue of $910 Million and Adjusted EPS of $1.85; Provides Fiscal 2016 Guidance 30
... June 1 /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd.,(Nasdaq: DHRM ... products in China , said today that it has become the ... Penlon, a UK firm specializing in anesthesia and breathing equipment for 60,years. ... ...
... CITY, Kan. , June 1 Oncimmune ... test that aids physicians in risk assessment and the ... results demonstrating the diagnostic and economic benefits of a ... significantly improve the prognosis for lung cancer patients. Currently, ...
... ... eLadder® Safety course series into its curriculum. The online drug safety training courses ... to enrolled PharmD and PhD students, postdoctoral fellows, and residents via the University of ... ...
Cached Biology Technology:Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 2Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 3Dehaier Medical Systems Extends Product Offerings with Exclusive Distribution Agreement for Penlon Anesthesia System in North China 4Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 2Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 3Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 4Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 5Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 6Studies Demonstrate Early Stage Detection and Economic Benefits of a Blood-Based Test for Lung Cancer 7University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 2University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 3University of Maryland School of Pharmacy Adopts BioSoteria's eLearning Drug Safety Courses 4
Human Serum FDA Licensed US Donor Centers Sterile / Non-sterile: Sterile Filtered to 0.2 micron Information: Extensive Viral Testing ...
Normal human AB serum, pooled...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Human/Mouse/Rat JNK Pan Specific Affinity Purified PAb...
Biology Products: